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Prevalence and duration of non-motor symptoms in prodromal
Parkinson's disease
Abstract

Background and purpose: The prevalence and duration of non-motor symptoms (NMS) in prodromal
Parkinson's disease (PD) has not been extensively studied. The aim of this study was to determine the
prevalence and duration of prodromal NMS (pNMS) in a cohort of patients with recently diagnosed PD.
Methods: We evaluated the prevalence and duration of pNMS in patients with early PD (n = 154). NMS were
screened for using the Non-Motor Symptom Questionnaire (NMSQuest). We subtracted the duration of the
presence of each individual NMS reported from the duration of the earliest motor symptom. NMS whose
duration preceded the duration of motor symptoms were considered a pNMS. Individual pNMS were then
grouped into relevant pNMS clusters based on the NMSQuest domains. Motor subtypes were defined as
tremor dominant, postural instability gait difficulty (PIGD) and indeterminate type according to the
Movement Disorder Society Unified Parkinson's Disease Rating Scale revision.
Results: Prodromal NMS were experienced by 90.3% of patients with PD and the median number
experienced was 4 (interquartile range, 2-7). A gender difference existed in the pNMS experienced, with
males reporting more sexual dysfunction, forgetfulness and dream re-enactment, whereas females reported
more unexplained weight change and anxiety. There was a significant association between any prodromal
gastrointestinal symptoms [odds ratio (OR), 2.30; 95% confidence interval (CI), 1.08-4.89, P = 0.03] and
urinary symptoms (OR, 2.54; 95% CI, 1.19-5.35, P = 0.016) and the PIGD phenotype. Further analysis
revealed that total pNMS were not significantly associated with the PIGD phenotype (OR, 1.10; 95% CI,
0.99-1.21, P = 0.068).
Conclusions: Prodromal NMS are common and a gender difference in pNMS experienced in prodromal PD
may exist. The PIGD phenotype had a higher prevalence of prodromal gastrointestinal and urinary tract
symptoms.
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Background and purpose: The prevalence and duration of non-motor symptoms (NMS) in prodromal Parkinson’s disease (PD) has not been extensively
studied. The aim of this study was to determine the prevalence and duration
of prodromal NMS (pNMS) in a cohort of patients with recently diagnosed
PD.
Methods: We evaluated the prevalence and duration of pNMS in patients
with early PD (n = 154). NMS were screened for using the Non-Motor Symptom Questionnaire (NMSQuest). We subtracted the duration of the presence
of each individual NMS reported from the duration of the earliest motor
symptom. NMS whose duration preceded the duration of motor symptoms
were considered a pNMS. Individual pNMS were then grouped into relevant
pNMS clusters based on the NMSQuest domains. Motor subtypes were
deﬁned as tremor dominant, postural instability gait diﬃculty (PIGD) and
indeterminate type according to the Movement Disorder Society Uniﬁed
Parkinson’s Disease Rating Scale revision.
Results: Prodromal NMS were experienced by 90.3% of patients with PD
and the median number experienced was 4 (interquartile range, 2–7). A gender
diﬀerence existed in the pNMS experienced, with males reporting more sexual
dysfunction, forgetfulness and dream re-enactment, whereas females reported
more unexplained weight change and anxiety. There was a signiﬁcant association between any prodromal gastrointestinal symptoms [odds ratio (OR), 2.30;
95% conﬁdence interval (CI), 1.08–4.89, P = 0.03] and urinary symptoms
(OR, 2.54; 95% CI, 1.19–5.35, P = 0.016) and the PIGD phenotype. Further
analysis revealed that total pNMS were not signiﬁcantly associated with the
PIGD phenotype (OR, 1.10; 95% CI, 0.99–1.21, P = 0.068).
Conclusions: Prodromal NMS are common and a gender diﬀerence in pNMS
experienced in prodromal PD may exist. The PIGD phenotype had a higher
prevalence of prodromal gastrointestinal and urinary tract symptoms.

Introduction
Clinically, Parkinson’s disease (PD) has been deﬁned
by the presence of motor deﬁcits such as bradykinesia,
Correspondence: R. Durcan, Institute of Neuroscience, Campus for
Ageing and Vitality, Newcastle Upon Tyne NE4 5PL, UK (tel.:
0191 2081278; fax: 0191 2081251; e-mail:
Rory.Durcan@newcastle.ac.uk).

tremor, rigidity and postural instability [1]. However,
patients with PD also experience a variety of other
non-motor symptoms (NMS) such as mood disorders,
autonomic disturbances, cognitive impairment and
sleep dysfunction throughout their disease trajectory.
Non-motor symptoms can precede motor symptoms,
indicating that a prodromal symptomatic stage exists
in PD. The presence of hyposmia, constipation,
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depression and idiopathic rapid eye movement sleep
behaviour disorder are well-established symptoms that
signiﬁcantly increase the risk of development of PD [2].
The emerging concept of a prodromal phase of PD
has led the International Parkinson and Movement
Disorder Society task force to propose a new deﬁnition of PD; this deﬁnition would not base the diagnosis solely on motor symptoms but would also
incorporate NMS [3]. However, there is a paucity of
research investigating the frequency and time of onset
of NMS before the onset of the motor phase of PD.
Furthermore, little is known about the relationship
between particular clusters of prodromal NMS
(pNMS) and the development of subsequent PD
motor phenotypes, i.e. tremor dominant (TD), postural instability gait diﬃculty (PIGD) or indeterminate
type [4].
We aimed to explore the frequency and time of
onset of NMS before motor symptoms (pNMS) and
the role of gender on pNMS experienced. We hypothesized that distinct clusters of pNMS would be associated with PIGD motor phenotype.

Methods
Patient eligibility criteria and recruitment

Patients with recently diagnosed PD from Newcastle
upon Tyne and Gateshead were invited to take part in
the study between June 2009 and December 2011 as
part of the Incidence of Cognitive Impairment in
Cohorts with Longitudinal Evaluation-Parkinson’s
Disease (ICICLE-PD) study [5].
All participants were diagnosed by a movement disorders specialist according to the UK Brain Bank criteria [1]. Exclusion criteria comprised the following:
drug-induced parkinsonism secondary to exposure to
dopamine receptor blocking agent at the onset of symptoms; vascular parkinsonism; and atypical forms of
parkinsonism such as progressive supranuclear palsy,
multiple system atrophy or corticobasal degeneration,
according to accepted diagnostic criteria [6]. Participants were also excluded if they had insuﬃcient working knowledge of English, deﬁned as being unable to
perform the assessments and questionnaires in the opinion of the assessor, or signiﬁcant memory impairment
or dementia at presentation, deﬁned by a Mini-Mental
State Examination score <24, fulﬁlling DSM-IV criteria
for dementia [7] or Movement Disorder Society criteria
for Parkinson’s disease dementia [8].
The study was approved by the Newcastle and
North Tyneside Research Ethics Committee and performed according to the Declaration of Helsinki. All
participants provided informed written consent.

Assessments

Participants with PD were rated for disease severity
by Hoehn & Yahr staging and motor severity using
the Movement Disorder Society Uniﬁed Parkinson’s
Disease Rating Scale part III. Motor subtypes were
deﬁned as TD, PIGD and indeterminate type according to the methods described by Stebbins et al. [9].
Due to the small numbers with indeterminate motor
phenotype in the cohort, only comparisons between
motor subtype of TD and PIGD were conducted.
Levodopa equivalent daily dose (LEDD) was calculated for all dopaminergic medications using methods
described by Tomlinson et al. [10].
Global cognition was assessed using the Mini-Mental State Examination and Montreal Cognitive Assessment. Depressive symptoms were also assessed using
the Geriatric Depression Scale-15.
Assessment of non-motor symptoms and prodromal
non-motor symptoms

Participant NMS burden was assessed at the initial
patient screening visit using the Non-Motor Symptom Questionnaire (NMSQuest) [11]. The NMSQuest
is a 30-item questionnaire that comprises 10
domains of NMS: gastrointestinal (GI) symptoms,
urinary tract symptoms, sexual function, cardiovascular issues, depression/anxiety, sleep problems/fatigue, pain and a number of other complaints such
as weight loss. A positive response about the
presence of an NMS on the screening questionnaire
elicited a further question about the estimated duration of the NMS symptom.
In order to determine the presence or absence of
pNMS, we subtracted the duration of the presence of
each individual NMS reported from the duration of
earliest motor symptom. NMS whose duration preceded the duration of motor symptoms were considered a pNMS, whereas NMS that occurred after
motor symptom onset were not classiﬁed as pNMS.
The presence and duration of each NMS in excess of
the duration of motor symptoms were recorded as a
pNMS in months.
Individual pNMS symptoms were further classiﬁed
into seven distinct non-motor subtypes based on the
symptom domains covered in the NMSQuest. These
were GI symptoms, urinary tract symptoms, sexual
dysfunction, cardiovascular symptoms, neuropsychiatric and cognitive symptoms, sleep dysfunction symptoms and miscellaneous symptoms. In order to be
included in a prodromal non-motor subtype, a participant had to have at least one pNMS consistent with
that NMS domain.
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Table 1 Characteristics of patients with Parkinson’s disease (PD)
(n = 154)

Statistical analysis

Statistical analyses were performed using SPSS software (Version 22, IBM Corp., Armonk, NY, USA).
Data were assessed for normality using Kolmogorov–
Smirnov tests. The mean and SD were computed for
parametric variables, and the median and interquartile
range for non-parametric variables. Continuous and
count data were compared using the parametric (ttest) or non-parametric (Mann–Whitney U-test) test
as appropriate and categorical data were compared
with chi-squared tests.
Hierarchical logistic regression was used to determine signiﬁcant predictors of PIGD motor phenotype.
Backwards stepwise logistic regression was used to
produce a basic model of predictors involving age,
gender and LEDD. Non-signiﬁcant predictors were
excluded. Signiﬁcant predictors were then included to
give a basic model and total pNMS and pNMS
domains (present or absent) were then individually
added to the model. P < 0.05 was deemed to be signiﬁcant for all analyses.

Results
A total of 154 participants with a diagnosis of idiopathic PD were identiﬁed from the ICICLE-PD
cohort (Table 1). Participants had a mean age of
66.4  10.4 years and had a median PD duration of
4.7 months [64.9% (n = 100) were male}.
The presence or absence of pNMS was calculated
[139 (90.3%) participants experienced pNMS]
(Table 2). The median number of pNMS experienced
by the patients with PD was 4 (interquartile range, 2–
7). The most common individual pNMS experienced
were as follows: hyposmia (39.6%), forgetfulness/
memory complaints (36%), sialorrhea (33.8%), urinary urgency (30.2%) and anxiety (30.2%) (Table 2).
Gender diﬀerences in pNMS experienced were observed,
with males reporting signiﬁcantly more sexual dysfunction (22% vs. 3.7%, respectively, P = 0.003), forgetfulness (38% vs. 22.2%, respectively, P = 0.046)
and dream re-enactment (29% vs. 14.8%, respectively,
P = 0.049) compared with female participants
(Table 2). Conversely, females reported signiﬁcantly
greater unexplained weight change (13% vs. 4%,
respectively, P = 0.039) and anxiety (37% vs. 22%,
respectively, P = 0.046).
Individual pNMS symptoms were classiﬁed into
pNMS domains. The most frequent pNMS domains
were GI tract (67.5%), sleep (52.6%), urinary tract
(42.2%), cardiovascular system (32.5%) and miscellaneous systems (22.1%) (Table 3). In terms of the median duration of pNMS preceding motor symptom

Variable
Gender (male/female)
Age (years)
Duration of PD (months)
MDS-UPDRS III score
H&Y staging
H&Y stage
I
II
III
IV
V
PD medication treatment
Drug naive
Levodopa
Dopaminergic agonists
MAOB inhibitor
LEDD (mg/day)
Motor phenotype
PIGD
Indeterminate
TD
MMSE score
MoCA scorea
GDS-15 score

100 (64.9)/54 (35.1)
66.4 (10.4)
4.7 (2.6–8.1)
26.9  12.1
2.0  0.7
35 (22.7)
88 (57.1)
30 (19.5)
1 (0.6)
0
19 (12.3)
45 (29.2)
57 (37)
73 (47.4)
178.1  148.2
78 (50.6)
13 (8.4)
63 (40.9)
28.6  1.3
25.2  3.7
2.8  2.6

GDS-15, Geriatric Depression Scale-15; H&Y, Hoehn & Yahr;
LEDD, levodopa equivalent daily dose; MAOB, monoamine oxidase
B; MDS-UPDRS, Movement Disorder Society Uniﬁed Parkinson’s
Disease Rating Scale, revised; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PIGD, postural instability gait diﬃculty motor subtype; TD, tremor dominant motor
subtype. Data are given as mean  SD, n (%) and median (interquartile range). aMoCA completed in 140 patients with PD.

onset, sleep dysfunction ( 66 months), sexual dysfunction ( 60 months) and GI tract symptoms ( 59
months) had the longest latency period (Table 3).
When pNMS were grouped into symptom clusters,
males experienced signiﬁcantly more symptoms related
to sexual problems compared with female participants
(26% vs. 5.6%, respectively, P = 0.002, Table 3).
Females experienced signiﬁcantly more miscellaneous
symptoms compared with male participants (40.7%
vs. 19%, respectively, P = 0.004).
Prodromal NMS diﬀerences between motor phenotypes were then evaluated (Table 4). Participants classiﬁed as having PIGD were signiﬁcantly older than
those with TD subtypes (68.4  9.2 vs. 63.6  11
years, respectively, P = <0.01; Table 4). The Geriatric
Depression Scale-15 scores were slightly higher for the
PIGD subtype compared with the TD subtype
(3.12  2.4 vs. 2.27  2.3, respectively, P = 0.01), but
were still below the cut-oﬀ (≥5) for possible depression
in all subtypes. Participants with PIGD subtype were
prescribed signiﬁcantly higher doses of LEDD
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Table 2 Prevalence of non-motor symptoms (NMS) at screening and prodromal NMS (pNMS) in patients with Parkinson’s disease (PD) and
median duration before the development of motor symptoms
pNMS in males vs. females
pNMS
(n = 154)
No. of patients with PD with symptoms
No pNMS experienced
Gastrointestinal tract
Sialorrhea
Dysphagia
Nausea
Constipation
Bowel incontinence
Incomplete bowel emptying
Hyposmia
Weight change (unexplained)
Urinary tract
Urinary urgency
Nocturia
Sexual function
Sexual dysfunction
Impaired libido
Cardiovascular
Orthostatic symptoms
Falls
Lower limb swelling
Neuropsychiatric and cognitive
Forgetfulness/memory
Impaired concentration
Anxiety
Low mood
Loss of interest/apathy
Delusions
Visual hallucinations
Sleep
Daytime somnolence
Insomnia
Dream re-enactment
Vivid dream imagery
Restless legs
Miscellaneous
Diplopia
Hyperhydrosis
Pain (unexplained)

Time interval of NMS
preceding motor
symptoms (months)

139 (90.3)
4 (2–7)
47
18
3
38
4
26
55
11

(30.5)
(11.7)
(1.9)
(24.7)
(2.6)
(16.9)
(35.7)
(7.1)

Males
(n = 100)

4 (2–6.25)
33
25
25
108
175
55
148
13

(
(
(
(
(
(
(
(

18 to
27 to
48 to
105 to
516 to
31 to
218 to
12 to

3)
4)
24)
11)
1)
6)
26)
1)

34
11
1
24
2
17
32
4

(34)
(11)
(1)
(24)
(5)
(17
(32.0)
(4.0)

68
28
167
175
70

(
(
(
(
(

11 (7.1)
4 (2.6)
32 (20.8)

0.202
0.718
0.247
0.791
0.526
0.958
0.191
0.039

20 (20.0)
11 (11.0)
10 (10.0)

8 (14.8)
5 (9.3)
7 (13.0)

v2 = 0.6
v2 = 0.1
v2 = 0.3

0.426
0.735
0.576

8)
8)
12)
7)
8)

38
16
22
15
13
0
7

(38)
(16.0)
(22.0)
(15)
(13)
(0) NA
(7.0)

12
9
20
12
9
0
5

(22.2)
(16.7)
(37.0)
(22.2)
(16.7)
(0)
(9.3)

v2 =
v2 =
v2 =
v2 =
v2 =
NA
v2 =

25
5
29
25
14

(25)
(5)
(29.0)
(25.0)
(14.0)

7
5
8
10
14

(13)
(9.3)
(14.8)
(18.5)
(25.9)

v2
v2
v2
v2
v2

23 ( 31 to
13 ( 12 to
61 ( 75 to

(20.8)
(6.5)
(24.0)
(22.7)
(18.2)

1.6
0.1
1.3
0.1
0.4
<0.1
1.7
4.2

2)
2)
8)

28 (18.2)
16 (10.4)
17 (11.0)

32
10
37
35
28

=
=
=
=
=
=
=
=

0.003
0.198

22)
18)

( 17 to

v2
v2
v2
v2
v2
v2
v2
v2

v2 = 8.9
v2 = 1.7

89 ( 87 to
56 ( 96 to

to
to
to
to
to

(24.1)
(13)
(3.7)
(25.9)
(3.7)
(16.7)
(42.6)
(13.0)

2 (3.7)
3 (5.6)

24 (15.6)
15 (9.7)

36
33
36
31
25

13
7
2
14
2
9
23
7

0.649

22 (22.0)
12 (12)

25 (25)
18 (18)

(
(
(
(
(

U = 2850.5

0.389
0.72

12)
12)

36
37
99
20
20
NA
12

4 (2–7)

P-value

v2 = 0.7
v2 = 0.1

63 ( 65 to
82 ( 78 to

(32.5)
(16.2)
(27.3)
(17.5)
(14.3)
(0)
(7.8)

Test statistic

17 (31.5)
11 (20.4)

42 (27.3)
29 (18.8)

50
25
42
27
22
0
12

Females
(n = 54)

4)

79 to 12)
51 to 11)
178 to 16)
228 to 12)
49 to 6)

112 ( 109 to 19)
48 ( 93 to 11)
15 ( 23 to 6)

6 (6.0)
1 (1.0)
17 (17)

5 (9.3)
3 (5.6)
15 (27.8)

0.2

0.046
0.915
0.046
0.261
0.535
NA
0.618

3.1
1.0
3.9
0.8
3.4

0.079
0.306
0.049
0.36
0.067

v2 = 0.6
v2 = 2.9
v2 = 2.4

0.454
0.090
0.116

=
=
=
=
=

4.0
<0.11
4.0
<0.1
0.4

NA, not applicable. Data are given as n (%) and median (interquartile range).

compared with TD subtype (203.0  138.6 mg vs.
151.4  165.4 mg, respectively, P < 0.01; Table 4).
Predictors of PIGD motor phenotype were then
determined, ﬁrst using logistic univariate regression.
Signiﬁcant predictors included age, LEDD, Geriatric
Depression Scale-15 score, number of pNMS, GI
symptoms and urinary symptoms (Table S1).
Backwards regression revealed that only age
[b = 0.061; odds ratio (OR), 1.06; 95% conﬁdence
interval (CI), 1.02–1.11, P = 0.003] was a signiﬁcant
predictor of PIGD phenotype; a basic model was then
constructed with age and LEDD. LEDD was included

in the basic model as it was an important confounding
variable although it was not a signiﬁcant predictor of
PIGD phenotype. Total pNMS and pNMS domains
were then individually added to the model. Analysis
revealed that total pNMS was not a signiﬁcant predictor of having PIGD phenotype (OR, 1.10; 95% CI,
0.99–1.21 P > 0.05). However, there was a signiﬁcant
association between any prodromal GI symptoms (OR,
2.30; 95% CI, 1.08–4.89, P < 0.05) and urinary symptoms (OR, 2.54; 95% CI, 1.19–5.35, P < 0.05) and the
PIGD phenotype. Patients with PD with prodromal GI
symptoms were thus 2.3 times more likely to develop
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Table 3 Prevalence and median duration of prodromal non-motor symptoms (pNMS) according to distinct pNMS domains
pNMS in males vs. females

Symptom group

PD pNMS

Gastrointestinal tract
Urinary tract
Sexual function
Cardiovascular
Neuropsychiatric and cognitive
Sleep
Miscellaneous

104
65
32
50
19
81
34

(67.5)
(42.2)
(20.8)
(32.5)
(12.3)
(52.6)
(22.1)

Time interval of NMS preceding
motor symptoms (months)
58.5
45
60
12
39
66
12

(
(
(
(
(
(
(

217 to 16)
126 to 14)
119 to 29)
48 to 5)
132 to 14)
237 to 19)
48 to 8)

Males
(n = 100)

Females
(n = 54)

v2

P-value

67
38
26
35
55
55
19

37
20
3
15
30
25
22

<0.1
<0.1
9.6
0.8
<0.1
1.1
8.5

0.848
0.906
0.002
0.361
0.947
0.302
0.004

(67.0)
(38.0)
(26.0)
(35.0)
(55)
(55.0)
(19.0)

(68.5)
(37.0)
(5.6)
(27.8)
(55.6)
(46.3)
(40.7)

NMS, non-motor symptoms; PD, Parkinson’s disease. Data are given as n (%) and median (interquartile range).

Table 4 Demographics and prevalence of prodromal non-motor symptoms among Parkinson’s disease (PD) motor subtypes

Variable

PIGD
(n = 78)

TD
(n = 63)

Test statistic

P-value

Gender (male/female)
Age (years)
Duration of PD (months)
LEDD (mg/day)
MMSE score
MoCA scorea
GDS-15 score
MDS-UPDRS III score

56 (71.8)/22(28.2)
68.4 (9.2)
6.2 (4.8)
203.04  138.61
28.53 (1.3)
24.77 (3.6)
3.12 (2.4)
26.96 (12.1)

36 (57.1)/27 (42.9)
63.6 (10.97)
5.7 (4.4)
151.4  165.4
28.8 (1.3)
25.6 (3.7)
2.3 (2.3)
26.2 (12.1)

v2
t
U
U
U
U
U
U

0.069
0.007
0.737
0.001
0.106
0.117
0.011
0.556

=
=
=
=
=
=
=
=

3.3
2.7
2376.0
1684.5
2081.0
1709.0
1849.5
2315.0

GDS-15, Geriatric Depression Scale-15; LEDD, levodopa equivalent daily dosage; MDS-UPDRS, Movement Disorder Society Uniﬁed Parkinson’s Disease Rating Scale, revised; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PIGD, postural instability gait diﬃculty motor subtype; TD, tremor dominant motor subtype. Data are given as mean  SD and n (%) unless otherwise stated.
Signiﬁcant results are highlighted in bold. aMoCA completed in 140 patients with PD.

PIGD phenotype, after controlling for age and LEDD.
Similarly, participants with PD with prodromal urinary
symptoms were 2.5 times more likely to evolve into a
PIGD rather than TD phenotype, after controlling for
age and LEDD (Supporting Information).

Discussion
Our study strengthens the notion of NMS antedating
motor symptoms in PD by assessing the presence and
time of onset of the full spectrum of pNMS using a
validated NMS questionnaire (NMSQuest) in a population with recently diagnosed PD. Interpretation of
previous studies evaluating the frequency and duration of onset of pNMS is limited by study methodological variability, lack of direct patient evaluation
[2], long duration from PD diagnosis to study enrolment [12], utilization of non-validated, custom-made
NMS questionnaires [13] or studying only limited subsets of the spectrum on pNMS in PD cohorts [14] or
‘at risk’ of PD cohorts [15,16].
Our study found 90% of participants reporting at
least one pNMS, whereas the median number of
pNMS experienced was four. Previous studies have

reported higher prevalence of prodromal symptoms
than our study, probably due to methodological differences. A retrospective study conducted via telephone interview with patients with PD and controls,
using a custom-made questionnaire, reported 98.9%
of subjects with PD having one or more prodromal
symptoms but this study incorporated prodromal
motor symptoms as well as pNMS [2]. Similarly,
another retrospective study, with a long mean duration from PD diagnosis of 7.6  5.6 years, reported
98.9% of subjects experienced prodromal symptoms
preceding a diagnosis of PD [12].
Based on the Braak model of the hypothesized
spread of alpha-synuclein in PD, alpha synuclein
accumulation begins in the gut before progressing via
the vagus nerve to the brain [17]. Therefore, GI features should be a prominent early manifestation of
PD. Our study encompassed questions focusing on
the GI tract that had not been previously reported,
such as the prevalence of prodromal weight loss
(7.1%), dysphagia (11.7%) and incomplete bowel
emptying (16.9%). Prevalence of prodromal constipation symptoms (24.7%) and hyposmia (35.7%) have
previously been reported and are approximately in
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line with published work [2,13]. Clustering prodromal
GI symptoms together revealed that 67.5% of subjects
with PD had one or more GI symptoms antedating
motor symptom development in PD, which is consistent with the Braak model of early GI involvement in
PD. Moreover, GI clusters, as well as urinary tract
clusters, of pNMS were signiﬁcantly associated with
PIGD motor phenotype. To the best of our knowledge, no other study has shown an association
between pNMS clusters and early PD motor phenotype.
In contrast with other studies, the prevalence of
prodromal memory complaints (32.8%) and unexplained pain (20.8%) in our study is substantially
higher compared with previous reported work [12,13].
Meanwhile, the prevalence of apathy (14.8%) and
hyperhidrosis (2.6%) is signiﬁcant lower than in other
studies. The variability in reported prevalence rate of
pNMS may be due to individual’s perception and
reporting of NMS. Many NMS progress slowly and
are of mild severity, so are underappreciated in the
early stages [12]. Furthermore, cognitive impairment
has also been associated with underestimation of NMS
and loss of awareness of hyposmia has been reported
to occur in Parkinson’s disease mild cognitive impairment [18]. It is possible that cognitive performance
may have impacted on symptom recall in our study as
the mean Montreal Cognitive Assessment score was
25.2 (3.7) and previously published work from
the ICICLE-PD study showed that, among the ﬁve
cognitive domains, memory impairment was the most
common domain aﬀected in participants with PD at
1.5 SDs below normative values (15.1%) [5]. However, all participants enrolled in the study underwent
rigorous assessment to exclude dementia.
Gender has been reported as an independent predictor of NMS reported in early PD studies. Females have
been reported to experience more anxiety, pain, depression and sleep disturbance [19–21], whereas males have
been reported to experience more apathy and sexual
dysfunction [22–24]. However, there is a paucity of
work examining the inﬂuence of gender on NMS in
the prodromal period. We found a gender diﬀerence
in terms of speciﬁc pNMS experienced, namely sexual
dysfunction, forgetfulness and dream re-enactment
being more prevalent in males, and unexplained weight
change and anxiety being more prevalent in females.
Gender diﬀerences in perceived pNMS prevalence may
be reﬂective of what each gender interprets to be
important rather than any underlying early pathological evolutionary diﬀerence between genders.
There are some limitations in our study. The retrospective design of this study may have introduced
recall error and thereby aﬀected the accuracy of the

data. Attempts were made to minimize recall errors
by having experienced movement disorder physicians
conduct face-to-face interviews with patients with
recently diagnosed PD, including a caregiver interview. Another limitation is the lack of a validated
prodromal questionnaire to evaluate pNMS.
NMSQuest was adapted to identify pNMS as is has
been extensively used to investigate NMS in de-novo,
early PD. However, its sensitivity and speciﬁcity for
evaluating prodromal symptoms in ‘at risk’ PD
cohorts have not been established. Therefore, it is
entirely possible that some of the symptoms reported
in this study are not related to an evolving Lewy body
disorder but other underlying medical conditions or
non-speciﬁc normal age-related symptoms.
In conclusion, our study has shown that pNMS are
prevalent, antedate motor symptoms in some cases by
several years and distinct gender diﬀerences exist in
the pNMS experienced. Furthermore, prodromal GI
and urinary tract symptoms were associated with the
PIGD motor phenotype.
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